SINGAPORE – The Singapore Institute of Advanced Medicine (Siam), a provider specializing in cancer treatment, has found itself under close scrutiny following concerning revelations from its auditor about the company’s operational viability.

The Dec 9 audit report has raised alarm bells among shareholders and drawn inquiries from the bourse regulator, igniting a fiery debate about Siam's decision to go public on Catalist prematurely.

The auditor’s findings not only cast doubts over Siam’s future but also prompted a discussion regarding the responsibilities of the company, its sponsor PrimePartners Corporate Finance, and Singapore Exchange Regulation (SGX RegCo) in ensuring that investors were adequately informed about the business's precarious financial situation.

This situation highlights a critical issue for investors on the Catalist board: the necessity to balance ambition with a greater acceptance of risk.

As the landscape of Singapore’s stock market changes, the role of risk is becoming increasingly important.

Experts suggest that for the Catalist market to thrive, investors must adapt by embracing not only the potential for growth but also the likelihood of market fluctuations and company-specific challenges.

Risks in the Catalist market often stem from companies that have innovative but unproven business models, as reflected in Siam’s case.

Investors are encouraged to conduct thorough due diligence and remain vigilant about the companies in which they place their capital. The current predicament faced by Siam serves as a stark reminder of the volatility inherent in nascent markets and sectors.

As Singapore’s economy continues to evolve, the Catalist market may provide unique opportunities for savvy investors willing to ride the waves of uncertainty.

Will you be one of them? It’s time to buckle up and prepare for the thrilling ride of investment in Singapore’s stock market!